| Ytd | -9.33% | |
| 1y | 133.33% |
| Open | 1.76 | Prev Close | 1.75 | Low | 1.71 | High | 2.11 | Mkt Cap | 86.94M |
| Vol | 5.04M | Avg Vol | 924.81K | EPS | -0.56 | P/E | N/A | Forward P/E | -1.44 |
| Beta | -3.37 | Short Ratio | 1.92 | Inst. Own | 31.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-22 | 50-d Avg | 1.71 | 200-d Avg | 1.76 | 1yr Est | 3.60 |
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporti
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporti
Raymond James analyst Martin Auster initiates coverage on iBio (NASDAQ:IBIO) with a Outperform ra
iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innov